로딩 중…
지수 로딩 중…
ST Pharm Co.,Ltd.
237690· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩121,800-4.09%
2026-06-19
Price Chart
ST Pharm Co.,Ltd.+57.57%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 2.54T KRW |
| Revenue | 346.22B KRW |
| Net Income | 69.05B KRW |
| Total Assets | 849.94B KRW |
| Net Assets | 611.25B KRW |
| Employees | 1,328 |
| Value | |
| P/E | 36.81x |
| P/B | 4.16x |
| PEG | 0.02x |
| P/S | 7.34x |
| EV/EBITDA | 38.24x |
| FCF Yield | -1.30% |
| Profitability | |
| ROE | 11.30% |
| ROA | 8.12% |
| Op. Margin | 18.90% |
| Revenue Growth | 27.74% |
| Earnings Growth | 2044.80% |
| Financial Health | |
| Debt Ratio | 39.05% |
| Total Debt | 72.02B KRW |
| FCF | -33.08B KRW |
| Cash | 111.27B KRW |
| Current Ratio | 2.08x |
| Net Debt/EBITDA | -0.60x |
| Dividend | |
| Div. Yield | 0.39% |
| Div. Growth | 0.00% |
| Performance | |
| 1Y Return | 57.57% |
| 1M Return | -2.40% |
| From 52W High | -29.23% |
| 1Y MDD | -35.09% |
| Trading | |
| Volume | 112,120 shares |
| Foreign Own. | 13.25% |
| Per Share | |
| EPS | 3,370 KRW |
| BPS | 29,350 KRW |
Company Info
ST Pharm was founded as UCHEM Co., Ltd. in 2008, then changed its name after an absorption merger with Samchully Pharmaceutical in 2010, subsequently joining the Dong-A Socio Group. Leveraging its expertise in small molecule new drugs, the company has expanded into oligonucleotide therapeutics CDMO. ST Pharm holds the world's third-largest production capacity, initiated production with the expansion of its second oligonucleotide plant in 2025, and provides a one-stop service system encompassing new drug development, CRO, and CDMO. It is headquartered in Siheung-si, Gyeonggi-do.